Abstract Submission Guidelines

Follow the guidelines below to submit an abstract to IKCS: Europe.

• All submitters are required to create a free account with Swoogo (our new event platform) to access the abstract submitter.

IMPORTANT DATES:

• Abstract Submission Deadline (all submissions including LBA placeholder submissions due at this time): February 8, 2024

• LBA Final Data Submission Deadline (final data, results, and conclusions for LBA placeholder submissions due at this time): February 29, 2024,
  • Additional instructions will be sent to lead authors to complete their LBA submissions by March 14, 2024.
  Abstract Notifications will be sent to lead authors by the week of March 7, 2024

ABSTRACT SUBMISSION TYPES:

• Regular Abstract (All research types and summaries of new, ongoing, and updated research relating to kidney cancer will be considered)
• Trials in Progress Abstract (All research types that are open, enrolling, ongoing, and have not reached pre-specified endpoints for analysis.)
• Late-breaking Data Submission Abstract (Phase I, II, III, or IV trials and original, high-impact research that could impact practice and standard of care)
• Case Report (A report of the diagnosis, treatment, and follow up of an individual patient)

ABSTRACT SECTIONS:

• Abstract Title: The title should objectively describe the study and should not include proprietary drug names.
• Abstract Text: The abstract text should be no more than 300 words including the title and abstract body. Word count does not apply towards spaces, authors, and affiliations. IKCS does not have a standard format for abstracts. It does not need to be subdivided into Background, phMethods, Results, and Conclusions sections, but any well-written abstract should contain the elements in that basic order.
• Optional Abstract Graph, Illustration, or Table: One brief graph, illustration, or table is permitted. An image, or table should only be included if you think it will help to clarify a complex methodology or to summarize an involved set of results.
• Authors: The maximum number of authors permitted is 20.
  • Pharmaceutical industry authors are allowed to present abstracts in non-CME sessions (Poster Sessions). If an abstract is selected for presentation in a CME-session, and the presenter has an EACCME®-defined conflict of interest*, an alternate presenter must be identified. A non-named author can present a poster if written permission is provided by the lead author to [email protected].
  • *Conflict of interest: A set of conditions in which judgment or decisions concerning a primary interest (for example a patients’ welfare, the validity of research and/or quality of medical education) is unduly influenced by a secondary interest (personal or organizational benefit including financial gain, academic or career advancement, or other benefits to family, friends, or colleagues).
• Conflict of Interest Disclosure: Presenting authors must submit a Conflict of Interest disclosure identifying financial relationships with ACCME-defined ineligible companies. Co-authors do not need to submit a COI Disclosure.

ABSTRACT POLICIES:

• Confidentiality Policy: Abstracts are confidential at the time of submission. KCA will release full abstracts on the meeting platform website April 16, 2024, leading up to the meeting. Meeting registration is required to access the abstracts.
• Abstract Presentation Ownership: Abstract Presentations (PPT slides and Posters) are owned by the author.
• KCJ Open Access Policy
• Permissions Policy
• Abstract Presentation Ownership: Abstract Presentations (PPT slides and Posters) are owned by the author and will not be published/printed by KCA/KCJ.

PUBLICATION OF CONFERENCE PROCEEDINGS:

Following symposia participation, authors may be asked to contribute a concise manuscript for potential inclusion in a dedicated Kidney Cancer publication. Stay tuned for forthcoming details.

Abstract Submission Categories

Abstracts in the following categories will be considered for presentation:

• Basic Science
• Translational Research
• Disparities in Cancer, Care and Access
• Diagnostics
• Financial Toxicity – Care Delivery/Health Outcomes
• Imaging
• Patient-reported Outcomes
• Post-treatment Surveillance
• Prevention and Screening
• Quality of Care and Quality Improvement
• Real-World Evidence
• Survivorship
• Treatment Toxicities and Symptom Management
• Therapeutics (Systemic- Radiation Therapy, Ablation, Surgery, Interventional Radiology, Urology, Medical Oncology, etc.)
• Therapeutics (Local- Primary and Metastatis)
• Tumor Biology, Biomarkers, and Pathology
• Other

Late-Breaking Data Submission Guidelines

Abstracts submitted in this category are Phase I-IV trials, or original research that could impact practice and standard of care. LBAs should be studies where results and conclusions are not yet available by the February 8 deadline, but will be available by the February 29, 2024 deadline.

Abstracts submitted in this category must have a placeholder submission (all components except for Results and Conclusions sections) received by the February 8, 2024 abstract submission deadline.

Lead authors will receive separate instructions to complete LBA placeholder submissions by February 15, 2024.

Trials-In-Progress Abstract Submission Guidelines

Abstracts submitted in this category are ongoing and should not include data, results, nor conclusions.

TIP abstracts are open, enrolling, or ongoing and have not reached any protocol-specific endpoints for analysis, and consequently will only require the completion of the Background and Methods sections.

Abstracts in all phases of clinical research (I, II, III, IV) may be submitted.

TIP Abstracts, if accepted, are eligible for Poster Presentation. TIP abstracts are not eligible for Oral Presentation.

Encore Data

IKCS Meetings seek to highlight cutting edge research; therefore, submissions should reflect unpublished work. Encore Data is still accepted for submission under any of the abstract categories only if a novel aspect of that research is presented. If you feel your work is derivative, but still has novelty merits, highlight this fact and be clear about what advancements you made. The program committee maintains the ultimate discretion to accept or reject encore abstracts. Abstracts presented at past IKCS meetings will not be accepted. 

Abstract Review and Selection Process

Abstracts will be reviewed by the IKCS: Europe Scientific Planning Committee. Abstract notifications will be sent to lead authors in March 7, 2024,

IKCS: Europe 2024 Merit Awards

All award winners will be notified by March 7, 2024. All abstracts submitted will automatically be eligible for a Merit Award.  

Merit Awards are given to abstract authors who submit high-quality abstracts. Winners must be enrolled and in good standing in an oncology or urology training program, fellowship, or post-doctoral researcher position.

 Merit Award Eligibility Requirements:

• Submit an abstract  
• Must be enrolled and in good standing in an oncology or urology training program, fellowship, or post-doctoral researcher position.
• Must attend the meeting in person.
• In addition to the oral presentation, submitters must also produce a poster.

Selection Process:

The IKCS Scientific Planning Committee will select four recipients to receive a merit award for the best original submissions.

Winners:

All four winners will receive a complimentary registration to IKCS 2024 Europe, be recognized in the program booklet and on stage, and provided a speaking slot during the oral abstract session.

Top Rated Posters

Top rated poster awards are given to the top five posters after Merit Award selection. The organizing committee will select the top five posters. One presenter from each of the five abstracts selected must attend the Symposium to receive the award. Poster Ads Presenters will be selected from all abstracts to prepare a 2-minute PPT presentation (2 slides max) to succinctly showcase and promote the poster on Friday, April 19, 2024 at the IKCSEU24.

 Top Rated Poster Award Eligibility Requirements:

• Must be enrolled and in good standing in an oncology or urology training program, fellowship, or post-doctoral researcher position.
• Must attend the meeting in person.
• In addition to the oral presentation, submitters must also produce a poster

Selection Process:

The IKCS Scientific Planning Committee will select five recipients to receive a merit award for the best original submissions.

Winners:

All winners will be recognized in the program booklet, be selected for poster ads on stage (2-min ad to the main conference audience) and will receive a TOP ABSTRACT/POSTER ribbon.

Outstanding Visual Design Poster

Will be assigned on site. Requirements: posters Must be up before 12pm on Friday April 19.

Selection Process:

Planning committee selects on-site before the poster walk.

Winners

All Outstanding Visual Design Posters will receive recognition at the symposium.

Abstract Presenter Guidelines

All accepted abstracts and lead authors are required to present in-person at 2024 IKCS: Europe in Sitges, Spain. Accepted abstracts will be displayed at the live meeting and electronic versions will be available online.

All Abstract Presenters must register for the conference.

Oral Abstract Presenter Guidelines

• Presentation Format: Oral Abstract Presenters should prepare a 7-minute PPT presentation.
• Slide Upload Deadline: PPT slides are due in the presenter portal by March 22, 2024. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
• Conflict of Interest Disclosure: Oral Abstract Presentations must include in a COI Disclosure slide.
• Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by March 8, 2024. Requests received after this date cannot be guaranteed removal from the program.
• Corresponding Poster: Oral Abstract presenters should also prepare a poster presentation to accompany their oral presentation.
• 1-min Poster ad: Selected abstracts’ presenters are to create a brief, two-minute ad to attract visitors to their poster during the poster session. No slides will be allowed.

Poster Presenter Guidelines

• Poster Presenters should prepare a PDF and printed poster. Attendees will have the opportunity to visit posters in-person onsite and view electronic versions online.
• ePoster Deadline: Presenters should upload a PDF poster to the Speaker Portal by April 5th, 2024. We will try our best to process late files, however, files received after this date cannot be guaranteed inclusion in the conference platform.
• Printed Posters: Poster Presenters should bring a printed poster onsite to hang on an assigned poster board for the duration of the meeting.
• Size: Printed posters should not exceed 95 cm in height by 97 cm in width. This is the size of the Poster Board. Poster hanging materials will be provided onsite.
• Printing: Poster Presenters should arrange their own poster printing and carry their poster onsite. If a Poster Presenter is unable to attend in-person, they should arrange for a colleague to carry and present the poster onsite.
• KCA is not responsible for costs associated with printing and shipping posters.
• Template: No specific Poster Template is required.
• Withdrawal Deadline: All withdrawal requests must be sent in writing from the first author to [email protected] by March 8, 2024. Requests received after this date cannot be guaranteed removal from the program.

Abstract Release Information

Abstract titles will be released to the media March 28, 2024.

Poster Presentations will become available: April 16, 2024
PDF versions of presentation slides will become available during the specific session for the presentation.

Abstract submission closes February 15, 2024,

Please contact [email protected].